# Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

Study · id `cardio:ct-nct02664155` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02664155](<https://clinicaltrials.gov/study/NCT02664155>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02664155

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 203 participants.

## Technical summary

Registry record NCT02664155. Randomized; no masking; primary purpose treatment. Start 2016-10-19 (actual); primary completion 2021-11-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 203 participants (enrolled count; ClinicalTrials.gov record NCT02664155, source copy `cardio:ctgov-nct02664155-2022-10-19`, retrieved 2026-10-31)
- Started: 2016-10-19 (actual) (ClinicalTrials.gov record NCT02664155, source copy `cardio:ctgov-nct02664155-2022-10-19`, retrieved 2026-10-31)
- Primary completion: 2021-11-30 (actual) (ClinicalTrials.gov record NCT02664155, source copy `cardio:ctgov-nct02664155-2022-10-19`, retrieved 2026-10-31)
- Completion: 2022-05-30 (actual) (ClinicalTrials.gov record NCT02664155, source copy `cardio:ctgov-nct02664155-2022-10-19`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT02664155, source copy `cardio:ctgov-nct02664155-2022-10-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02664155-2022-10-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
- Acronym: VERDICT
- Condition: Renal Insufficiency
- Intervention (Drug): Apixaban
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Heparin
- Intervention (Drug): VKA
- Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
- Lead sponsor class: OTHER
- Collaborator: Ministry of Health, France
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Heparin (`cardio:heparin`)
- Registry lists this organization as the lead sponsor: Centre Hospitalier Universitaire de Saint Etienne (`cardio:org-centre-hospitalier-universitaire-de-saint-etienne`)
- Registry lists this organization as a collaborator: Ministry of Health, France (`cardio:org-ministry-of-health-france`)

## Provenance

Content hash: d11f615d5a4cc6811b9624616ad297817df6c269a2cd5405a8fa880ed18b61cc
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
